Wachtell Kristian, Devereux Richard B, Lyle Paulette A, Okin Peter M, Gerdts Eva
Department of Cardiology B2142, The Heart Center, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
Ther Adv Cardiovasc Dis. 2008 Dec;2(6):507-13. doi: 10.1177/1753944708093846. Epub 2008 Aug 21.
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study provided extensive data on predisposing factors, consequences, and prevention of atrial fibrillation (AF) in patients with hypertension and left ventricular (LV) hypertrophy. Randomized losartan-based treatment was superior to atenolol-based treatment for reducing new-onset AF and complications, especially stroke, associated with new-onset or pre-existing AF. Potential mechanisms of AF prevention by angiotensin receptor blockade supported by LIFE results include greater reduction in left atrial size and LV hypertrophy. Differential effects of antihypertensive treatment on the left atrium and left ventricle may help prevent AF and reduce risk of stroke associated with hypertensive heart disease.
氯沙坦降低高血压终点事件（LIFE）研究提供了关于高血压合并左心室肥厚患者房颤（AF）的易感因素、后果及预防的大量数据。基于氯沙坦的随机治疗在减少新发房颤及与新发或既往存在的房颤相关的并发症（尤其是卒中）方面优于基于阿替洛尔的治疗。LIFE研究结果支持的通过血管紧张素受体阻滞剂预防房颤的潜在机制包括更大程度地减小左心房大小和左心室肥厚。降压治疗对左心房和左心室的不同作用可能有助于预防房颤并降低与高血压性心脏病相关的卒中风险。
